KDM1A and endometrial carcinoma: In conclusion, we have demonstrated that the treatment of Type II endometrial carcinoma cell lines with the LSD1 inhibitor HCI2509 decreased proliferation and transformation, induced histone methylation and LSD1 target gene expression, perturbed cell cycle progression, and induced apoptotic cell death in vitro.